Citations

Clear

941 citation(s) found for "Tefferi, A".

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
Pardanani, Animesh , Brockman, Stephanie R., Paternoster, Sarah F., Flynn, Heather C., Ketterling, Rhett P. , Ho, Ching-Liang, Li, Chin‐Yang, Dewald, Gordon W., Tefferi, Ayalew , Lasho, Terra L. , Li, Chin‐Yang, Ketterling, Rhett P

Mayo Clinic

Blood | July 30, 2004 | Volume: 104 | Issue: 10 | Pages: 3038-3045

10.1182/blood-2004-03-0787 | PMID 15284118 Get It

Abstract A novel oncogenic mutation (FIP1L1-PDGFRA), which results in a constitutively activated platelet-derived growth factor receptor-α (PDGFRA), has been invariably associated with a primary eosinophilic disorder. The current study examines both the prevalence and the associated clinicopathologic features of this mutation in a cohort of 89 adult patients presenting with an absolute eosinophil count (AEC) of higher than 1.5 × 109/L. A fluorescence in situ hybridization (FISH)–based strategy was used to detect FIP1L1-PDGFRA in bone marrow cells. None of 8 patients with reactive eosinophilia displayed the abnormality, whereas the incidence of FIP1L1-PDGFRA in the remaining 81 patients with primary eosinophilia was 14% (11 patients). None (0%) of 57 patients with the hypereosinophilic syndrome (HES) but 10 (56%) of 19 patients with systemic mast cell disease associated with eosinophilia (SMCD-eos) carried the specific mutation. The bone marrow mast cell infiltration pattern in FIP1L1-PDGFRA+ SMCD-eos was distinctly diffuse with loose tumoral aggregates. Treatment with low-dose imatinib (100 mg/d) produced complete and durable responses in all 8 FIP1L1-PDGFRA+ cases treated. In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis.
Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature
Dispenzieri, Angela , Moreno‐Aspitia, Alvaro , Suárez, Guillermo A. , Lacy, Martha Q. , Colón‐Otero, Gerardo , Tefferi, Ayalew , Litzow, Mark R. , Kyle, Robert A. , Roy, Vivek , Hogan, William J. , Gertz, Morie A. , Dispenzieri, Angela

Mayo Clinic

Blood | July 27, 2004 | Volume: 104 | Issue: 10 | Pages: 3400-3407

10.1182/blood-2004-05-2046 | PMID 15280195 Get It

Abstract POEMS syndrome is characterized by peripheral neuropathy (PN), a clonal plasma cell disorder (PCD), organomegaly, endocrinopathy, skin changes, edema, sclerotic bone lesions, and thrombocytosis. Based on the improved response rates observed with peripheral blood stem cell transplantation (PBSCT) in patients with other PCDs, autologous PBSCT may be an attractive treatment option for this syndrome. Sixteen patients with POEMS syndrome have undergone PBSCT at Mayo. Of these patients, 15 had a severe rapidly progressive sensorimotor PN (9 were wheelchair dependent) and 14 were male. Median age was 51 years (range, 19-62 years). The median number of prior therapies was 3 (range, 0-7). From first symptoms and from diagnosis of POEMS the times to transplantation were 42 months and 5 months (ranges, 8-185 months and 2-149 months), respectively. There were 15 patients who had significantly abnormal pretransplant pulmonary function tests. There was one transplant-related death. During the peritransplant period, 5 patients required intubation for respiratory compromise, including one who required intubation during his stem cell mobilization period. Another patient required noninvasive biphasic positive airway pressure throughout his course. Of the 14 evaluable patients, all have had neurologic improvement or stabilization. Other features have improved substantially. PBSCT for POEMS syndrome is effective therapy but may also be associated with significant morbidity. (Blood. 2004;104:3400-3407)
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Pardanani, Animesh , Tefferi, Ayalew

Mayo Clinic

Blood | June 1, 2004 | Volume: 104 | Issue: 7 | Pages: 1931-1939

10.1182/blood-2004-01-0246 | PMID 15166033 Get It

Abstract Imatinib mesylate is a small molecule drug that in vitro inhibits the Abelson (Abl), Arg (abl-related gene), stem cell factor receptor (Kit), and platelet-derived growth factor receptor A and B (PDGFRA and PDGFRB) tyrosine kinases. The drug has acquired therapeutic relevance because of similar inhibitory activity against certain activating mutations of these molecular targets. The archetypical disease in this regard is chronic myeloid leukemia, where abl is constitutively activated by fusion with the bcr gene (bcr/abl). Similarly, the drug has now been shown to display equally impressive therapeutic activity in eosinophilia-associated chronic myeloproliferative disorders that are characterized by activating mutations of either the PDGFRB or the PDGFRA gene. The former usually results from translocations involving chromosome 5q31-33, and the latter usually results from an interstitial deletion involving chromosome 4q12 (FIP1L1-PDGFRA). In contrast, imatinib is ineffective, in vitro and in vivo, against the mastocytosis-associated c-kit D816V mutation. However, wild-type and other c-kit mutations might be vulnerable to the drug, as has been the case in gastrointestinal stomal cell tumors. Imatinib is considered investigational for the treatment of hematologic malignancies without a defined molecular drug target, such as polycythemia vera, myelofibrosis with myeloid metaplasia, and acute myeloid leukemia.
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
Dispenzieri, Angela , Kyle, Robert A. , Lacy, Martha Q. , Burritt, Mary F., Therneau, Terry M. , McConnell, Joseph P., Litzow, Mark R. , Gastineau, Dennis A., Tefferi, Ayalew , Inwards, David J. , Micallef, Ivana N. , Ansell, Stephen M. , Porrata, Luis F. , Elliott, Michelle A. , Rajkumar, S. Vincent , Fonseca, Rafaël , Greipp, Philip R., Lust, John A., Zeldenrust, Steven R., Snow, Denise S., Hayman, S. R., McGregor, Christopher G.A. , Jaffe, Allan S. , Gertz, Morie A. , Hogan, William J. , Witzig, Thomas E. , Jaffe, Allan S. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | March 30, 2004 | Volume: 104 | Issue: 6 | Pages: 1881-1887

10.1182/blood-2004-01-0390 | PMID 15044258 Get It

AbstractPrimary systemic amyloidosis (AL) is a fatal plasma cell disorder. Pilot data suggest survival is better in patients undergoing peripheral blood stem cell transplantation (PBSCT), but the selection process makes the apparent benefit suspect. We have reported that circulating cardiac biomarkers are the best predictors of survival outside of the transplantation setting. We now test whether cardiac troponins (cTnT and cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are prognostic in transplant recipients. In 98 patients with AL undergoing PBSCT, serum cardiac biomarkers were measured (cTnT, 98 patients; cTnI, 65 patients; and NT-proBNP, 63 patients). Elevated levels of cTnT, cTnI, and NT-proBNP were present in 14%, 43%, and 48% of patients, respectively. At 20 months median follow-up, median survival has not been reached for patients with values below the thresholds; in patients with values above the thresholds, median survival is 26.1 months, 66.1 months, and 66.1 months, respectively. Our previously reported risk systems incorporating these markers were also prognostic, notably the cTnT/NT-proBNP staging. Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT.
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
Dispenzieri, Angela , Kyle, Robert A. , Lacy, Martha Q. , Therneau, Terry M. , Plevak, Matthew F., Rajkumar, S. Vincent , Fonseca, Rafaël , Greipp, Philip R., Lust, John A., Zeldenrust, Steven R., Snow, Denise S., Hayman, S. R., Litzow, Mark R. , Gastineau, Dennis A., Tefferi, Ayalew , Inwards, David J. , Micallef, Ivana N. , Ansell, Stephen M. , Porrata, Luis F. , Elliott, Michelle A. , Larson, Dirk R. , Witzig, Thomas E. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | January 27, 2004 | Volume: 103 | Issue: 10 | Pages: 3960-3963

10.1182/blood-2003-12-4192 | PMID 14739213 Get It

AbstractPrimary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case-match-control study comparing overall survival of 63 AL patients undergoing transplantation with 63 patients not undergoing transplantation. Matching criteria included age, sex, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24-hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to sex (57% males), age (median, 53 years), left ventricular ejection fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL [97.24 μmol/L]), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups, respectively, the 1-, 2-, and 4-year overall survival rates are 89% and 71%; 81% and 55%; and 71% and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL.
Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia
Tefferi, Ayalew , Wolanskyj, Alexandra P. , Lasho, Terra L. , Mesa, Ruben A. , Wolanskyj-Spinner, Alexandra P

Mayo Clinic

Blood | January 5, 2004 | Volume: 103 | Issue: 9 | Pages: 3547-3548

10.1182/blood-2003-10-3505 | PMID 14701686 Get It

Abstract Recent studies have demonstrated neutrophil overexpression of the polycythemia rubra vera-1 (PRV-1) gene in polycythemia vera (PV) but not in secondary or spurious polycythemia (SP). To validate as well as expand upon this novel observation, we conducted a prospective study of 88 subjects: 30 with PV, 22 with SP, 14 with essential thrombocythemia (ET), 12 with myelofibrosis with myeloid metaplasia (MMM), and 10 controls. To minimize interstudy methodologic differences, we used a published real-time polymerase chain reaction (PCR)-based assay. The proportion of patients with increased neutrophil PRV-1 expression was 83% in PV, 21% in ET, 42% in MMM, 18% in SP, and 0% in controls. All 5 MMM patients with PRV-1 up-regulation had an antecedent history of PV. We conclude that neutrophil PRV-1 up-regulation is a characteristic feature of PV that may not be affected by fibrotic transformation. However, quantifying neutrophil PRV-1 mRNA, while complementary to other tests, is not in itself sufficient for the diagnosis of PV. (Blood. 2004;103:3547-3548)
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
Hackbarth, Jennifer S., Le, Son B. , Loegering, David A., Bone, Nancy D., Bruzek, Laura M., Narayanan, V. L. , Adjei, Alex A. , Tefferi, Ayalew , Karp, Judith E. , Sausville, Edward A., Chandra, Joya , Kay, Neil E. , Kaufmann, Scott H.

Mayo Clinic

Blood | August 19, 2003 | Volume: 102 | Issue: 13 | Pages: 4512-4519

10.1182/blood-2003-02-0562 | PMID 12920036 Get It

Abstract Adaphostin (NSC 680410), an analog of the tyrphostin AG957, was previously shown to induce Bcr/abl down-regulation followed by loss of clonogenic survival in chronic myelogenous leukemia (CML) cell lines and clinical samples. Adaphostin demonstrated selectivity for CML myeloid progenitors in vitro and remained active in K562 cells selected for imatinib mesylate resistance. In the present study, the mechanism of action of adaphostin was investigated in greater detail in vitro. Initial studies demonstrated that adaphostin induced apoptosis in a variety of Bcr/abl- cells, including acute myelogenous leukemia (AML) blasts and cell lines as well as chronic lymphocytic leukemia (CLL) samples. Further study demonstrated that adaphostin caused intracellular peroxide production followed by DNA strand breaks and, in cells containing wild-type p53, a typical DNA damage response consisting of p53 phosphorylation and up-regulation. Importantly, the antioxidant N-acetylcysteine (NAC) blunted these events, whereas glutathione depletion with buthionine sulfoximine (BSO) augmented them. Collectively, these results not only outline a mechanism by which adaphostin can damage both myeloid and lymphoid leukemia cells, but also indicate that this novel agent might have a broader spectrum of activity than originally envisioned. (Blood. 2003;102:4512-4519)
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
Pardanani, Animesh , Ketterling, Rhett P. , Brockman, Stephanie R., Flynn, Heather C., Paternoster, Sarah F., Shearer, Brandon M., Reeder, Terra L. , Li, Chin‐Yang, Cross, Nicholas C.P. , Cools, Jan , Gilliland, D. Gary, Dewald, Gordon W., Tefferi, Ayalew , Li, Chin‐Yang, Ketterling, Rhett P , Cross, Nicholas C P

Mayo Clinic

Blood | July 8, 2003 | Volume: 102 | Issue: 9 | Pages: 3093-3096

10.1182/blood-2003-05-1627 | PMID 12842979 Get It

AbstractImatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either abl- or PDGFRβ- activating mutations. The drug is also active in a subset of patients with eosinophilic disorders and systemic mast cell disease (SMCD). Recently, a novel tyrosine kinase that is generated from fusion of the Fip1-like 1 (FIP1L1) and PDGFRα (PDGFRA) genes has been identified as a therapeutic target for imatinib mesylate in hypereosinophilic syndrome (HES). We used fluorescence in situ hybridization (FISH) to detect deletion of the CHIC2 locus at 4q12 as a surrogate for the FIP1L1-PDGFRA fusion. CHIC2 deletion was observed in bone marrow cells for 3 of 5 patients with SMCD associated with eosinophilia. Deletion of this locus and expression of the FIP1L1–platelet-derived growth factor receptor α (PDGFRA) fusion was also documented in enriched eosinophils, neutrophils, or mononuclear cells by both FISH and reverse transcriptase–polymerase chain reaction (RT-PCR) for one patient. While all 3 patients with the FIP1L1-PDGFRA rearrangement achieved a sustained complete response with imatinib mesylate therapy, the other two, both carrying the c-kit Asp816 to Val (Asp816Val) mutation, did not. These observations suggest that the FIP1L1-PDGFRA rearrangement occurs in an early hematopoietic progenitor and suggests that the molecular pathogenesis for a subset of SMCD patients is similar to that of HES. Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD.
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
Pardanani, Animesh , Reeder, Terra L. , Porrata, Luis F. , Li, Chin‐Yang, Tazelaar, Henry D. , Baxter, E. Joanna , Cross, Nicholas C.P. , Tefferi, Ayalew , Li, Chin‐Yang, Tazelaar, Henry D. , Witzig, Thomas E. , Baxter, Elizabeth Joanna , Cross, Nicholas C P

Mayo Clinic

Blood | April 21, 2003 | Volume: 101 | Issue: 9 | Pages: 3391-3397

10.1182/blood-2002-10-3103 | PMID 12506022 Get It

Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality. In the current study, we sought to confirm the preliminary observations in HES as well as evaluate the therapeutic value of imatinib in eos-CMD that is not associated with t(5;12)(q33;p13). Five patients with HES (all men, median age = 46 years) and 2 with eos-CMD (both men, aged 45 and 58 years) were treated with imatinib at a starting dose of 100 to 400 mg/day. Cytogenetic studies showed no evidence of either the bcr-abl translocation or t(5;12)(q33;p13) in any patient. Screening of exons encoding the intracellular catalytic domains and extracellular ligand binding domains of PDGFRβ (exons 2-23) and c-kit (exons 1-21) in 6 patients demonstrated mostly previously known polymorphisms. At a median follow-up of 17 weeks (range, 10-33 weeks), 2 patients with HES and 1 with eos-CMD have achieved complete clinical remission and 1 additional patient with HES has achieved a partial remission. In contrast to previous observations, all 4 responding patients had elevated serum interleukin-5 levels. Although the drug was well tolerated in most patients, a previously unrecognized treatment toxicity of acute left ventricular dysfunction occurred in a responding patient with HES within the first week of treatment. Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy.
‘Les cytokinès responsables’ in osteosclerosis and myelofibrosis
Tefferi, Ayalew

Mayo Clinic

Blood | April 2, 2003 | Volume: 101 | Issue: 8 | Pages: 2903-2903

10.1182/blood-2003-02-0561 Get It